Industry: Drug Manufacturing, Pharmaceuticals, Biotechnology
Corcept Therapeutics Incorporated is a pharmaceutical company engaged in the development of drugs for the treatment of severe psychiatric and neurological diseases. Corcept’s lead product, CORLUX, is currently in Phase III clinical trials for the treatment of the psychotic features of PMD. The drug is administered orally to PMD patients once per day for seven days. CORLUX, a potent GR-II antagonist, appears to mitigate the effects of the elevated and abnormal release patterns of cortisol seen in PMD. The Company is also conducting a proof-of-concept study evaluating the ability of CORLUX to mitigate weight gain associated with the use of olanzapine. ( www.corcept.com )
Corcept Therapeutics Incorporated
149 Commonwealth Drive
Menlo Park, California 94025
USA
Tel: (650) 327-3270
Fax: (650) 327-3218